Table 1 Summary of completed phase IIb / III HIV-1 vaccine trials
Vaccine trial | Candidate vaccine(s) | Phase | N volunteers | Intended immune response | Result |
|---|---|---|---|---|---|
VAX 003 | Protein: rgp120 | III | 2500 | Antibodies, CD4+ T cells | No efficacy |
VAX 004 | Protein: rgp120 | III | 5400 | Antibodies, CD4+ T cells | No efficacy |
RV144 | Pox/protein: ALVAC/rgp120 | III | 16,403 | Antibodies, CD4+ & CD8+ T cells | 31% efficacy |
HVTN 502/ Merck 023 | Adenovirus type 5 (Ad5) gag/pol/nef | IIb | 3000 | CD8+ & CD4+ T cells | No efficacy |
HVTN 503 | Ad5 gag/pol/nef | IIb | 3000 | CD8+ & CD4+ T cells | No efficacy |
HVTN 505 | DNA-Ad5 gag/pol/nef/env | IIb | 2504 | Antibodies, CD4+ & CD8+ T cells | No efficacy |